Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Oteseconazole provides a valuable step forward, but long-term studies are still needed to fully assess its safety, effectiveness across populations, and utility in additional indications beyond RVVC
Learn more about speak with a personal injury lawyer, or contact us for a free evaluation
Omega-3s for inflammation and heart health
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Tirzepatide (GLP-1/GIP) Also known as: Mounjaro, Zepbound, LY3298176, dual incretin, twincretin, GIP/GLP-1 dual agonist Summary Tirzepatide (Mounjaro, Zepbound) is the first dual GIP/GLP-1 receptor agonist two incretin pathways in one molecule
In March 2026, Lilly also reported positive Phase 3 data for retatrutide in type 2 diabetes
US$ 21.33
US$ 22.82
US$ 25.58
US$ 25.43
US$ 20.21
US$ 26.10
US$ 23.22
US$ 29.79
US$ 20.14
